Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 27 July 2020, 15:18 HKT/SGT
Share:
    

Source: Aptorum Group Limited
Aptorum Group Becomes the First Nasdaq Listed Biopharmaceutical Company Admitted to Trading on Euronext Paris Stock Exchange Under the Ticker Symbol APM

HONG KONG, July 27, 2020 - (ACN Newswire) - Aptorum Group Limited (Nasdaq: APM) ("Aptorum Group"), a biopharmaceutical company focusing on the development of novel therapeutics to address global unmet medical needs, today is pleased to announce that its Class A Ordinary Shares has commenced trading on the Professional Compartment of Euronext in Paris under the Euronext ticker symbol "APM" and ISIN Code: KYG6096M1069. Aptorum Group's Class A Ordinary Shares continues to be listed on the Nasdaq Global Market under the symbol APM.


Mr. Darren Lui, President and Executive Director (left), at the Euronext Paris Stock Exchange ceremony


The 7,950,986 Class A Ordinary Shares of Aptorum Group got admitted to trading on Euronext market in Paris after Aptorum Group received a visa for its prospectus granted by the French Autorite des Marches Financiers on 16 July 2020.

Reed Smith LLP acts as Aptorum Group's legal advisor and listing agent. BNP Paribas Securities Services acts as Aptorum Group's trading agent.

About Aptorum Group
Aptorum Group Limited (Nasdaq: APM) is a pharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle current unmet medical needs. Aptorum Group's current drug pipeline includes indications in orphan diseases, infectious diseases and metabolic diseases, a number of which are targeted to enter clinical trial phases. Aptorum Group is also launching a women's health supplement, dioscorea opposita bioactive nutraceutical tablets marketed under the brand name NativusWell.

For more information about Aptorum Group, please visit our website: www.aptorumgroup.com.

Disclaimer and Forward-Looking Statements

This press release does not constitute an offer to sell or a solicitation of offers to buy any securities of Aptorum Group.

This annoucement is not a prospectus within the meaning of the Regulation (EU) n 2017/1129 of 14 June 2017 as amended by Regulations Delegated (EU) n 2019/980 of 14 March 2019 and n 2019/979 of 14 March 2019.

This press release includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the US Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions and trials, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future and the prospectus that received the French Autorite des Marches Financiers visa n 20-352 on 16 July 2020. As a result, the projections included in such forward-looking statements are subject to change and could be materially different from those described herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
This press release is provided "as is" without any representation or warranty of any kind.

Investor relations contacts
Aptorum Group limited
Investor Relations Department:
Tel: +852 3953 7700
Email: [email protected]

Actifin - Financial Communications Europe
Investor relations
Ghislaine Gasparetto
[email protected]
+33 1 56 88 11 22

Redchip - Financial Communications United States
Investor relations
RedChip Companies, Inc.
[email protected]
+1 407 491 4498




July 27, 2020 15:18 HKT/SGT
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Aptorum Group Limited
Mar 30, 2020 22:09 HKT/SGT
Aptorum Group Collaborates with Covar Pharmaceuticals to Investigate 3 Repurposed Drug Candidates (SACT-COV19) for Coronavirus Disease 2019 (COVID-19) under Existing Smart-ACT Platform and Acticule Infectious Disease Platform
Mar 30, 2020 21:44 HKT/SGT
Aptorum Group Limited Corporate Update and To Hold Q1 2020 Investor Update Call To Discuss Recent Development and Pipeline Progress
Feb 24, 2020 20:13 HKT/SGT
Aptorum Group Commences Commercialization of Dioscorea Opposita Bioactive Nutraceutical Tablets and Signed Sales Distribution Agreement in Hong Kong
Feb 11, 2020 11:14 HKT/SGT
Aptorum Group Announces Further Positive Data for its ALS-4 Small Molecule Anti-virulence (Non-bactericidal) Drug Candidate for Treatment of Infections caused by Staphylococcus Aureus
Feb 10, 2020 22:58 HKT/SGT
Aptorum Group Announces Significant Progress of Repurposed Drug Candidate, SACT-1 for Neuroblastoma Targeting IND Submission in H2 2020
Sept 10, 2019 13:01 HKT/SGT
Aptorum Group has initiated IND-Enabling Studies for its ALS-4 Small Molecule Candidate for the Treatment of Infections Caused by Staphylococcus Aureus including MRSA
Sept 10, 2019 12:36 HKT/SGT
Aptorum Group Announces the Development of Microbiome Drug Candidate Targeting Obesity and Repurposed Drug Candidates Targeting Neuroblastoma
Dec 7, 2018 15:59 HKT/SGT
Aptorum Group Limited Announces Pricing of Initial Public Offering
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: